Updates in the systemic treatment of hepatocellular carcinoma

Emerson Y. Chen, Charles Lopez, Gina Vaccaro

Research output: Contribution to journalReview article

Abstract

Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalEuropean Oncology and Haematology
Volume14
Issue number2
StatePublished - Jan 1 2018

Fingerprint

Hepatocellular Carcinoma
Phase III Clinical Trials
Pharmaceutical Preparations
Immunotherapy
Therapeutics

Keywords

  • Advanced disease
  • Cabozantinib
  • Hepatocellular carcinoma
  • Lenvatinib
  • Nivolumab
  • Ramucirumab
  • Regorafenib
  • Sorafenib

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Updates in the systemic treatment of hepatocellular carcinoma. / Chen, Emerson Y.; Lopez, Charles; Vaccaro, Gina.

In: European Oncology and Haematology, Vol. 14, No. 2, 01.01.2018, p. 76-81.

Research output: Contribution to journalReview article

@article{d0f53d4ed25b4831a512af1185cd0080,
title = "Updates in the systemic treatment of hepatocellular carcinoma",
abstract = "Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.",
keywords = "Advanced disease, Cabozantinib, Hepatocellular carcinoma, Lenvatinib, Nivolumab, Ramucirumab, Regorafenib, Sorafenib",
author = "Chen, {Emerson Y.} and Charles Lopez and Gina Vaccaro",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "76--81",
journal = "European Oncology and Haematology",
issn = "2045-5275",
publisher = "Touch Digital Media",
number = "2",

}

TY - JOUR

T1 - Updates in the systemic treatment of hepatocellular carcinoma

AU - Chen, Emerson Y.

AU - Lopez, Charles

AU - Vaccaro, Gina

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

AB - Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

KW - Advanced disease

KW - Cabozantinib

KW - Hepatocellular carcinoma

KW - Lenvatinib

KW - Nivolumab

KW - Ramucirumab

KW - Regorafenib

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85057822943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057822943&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85057822943

VL - 14

SP - 76

EP - 81

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 2

ER -